Allergan’s $51 Million Restasis Antitrust Deal Gets Final OK

Allergan and a group of drug distributors got the nod from a federal judge in Brooklyn for their $51 million settlement of allegations that the company used bogus patents and sham litigation to delay generic competition for the dry-eye treatment Restasis.

Judge Nina Gershon granted final approval to the agreement resolving proposed class action antitrust claims on behalf of “direct purchasers,” led by large wholesalers and retailers like Meijer Inc.

The judge also approved $16.4 million in attorneys’ fees and just shy of $2 million in litigation costs for class counsel, led by Hagens Berman Sobol Shapiro LLP, and an ...